Driver Instrument, part of the Superion Indirect Decompression System, REF: 102-9800, used with t...
FDA Device Recall #Z-1972-2023 — Class II — May 12, 2023
Recall Summary
| Recall Number | Z-1972-2023 |
| Classification | Class II — Moderate risk |
| Date Initiated | May 12, 2023 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Boston Scientific Neuromodulation Corporation |
| Location | Valencia, CA |
| Product Type | Devices |
| Quantity | 21,533 |
Product Description
Driver Instrument, part of the Superion Indirect Decompression System, REF: 102-9800, used with the Superion Indirect Decompression System IFU, Superion IDS Kit IFU, Surgical Technique Manual
Reason for Recall
Pending update to indirect decompression system instructions for use informing users that excessive force during the implant procedure may cause driver instrument tip breaks, which may result in metal fragments (Driver teeth/tips) within the implant location; and if metal fragments are not removed and remain in situ, MRI scans are NOT advised due to potential risk of patient injury.
Distribution Pattern
US Nationwide Distribution: IN, NY, IL, PA, FL, SC, TX, MA, VA, AL, WI, OK, MO, MI, OH, WV, NC, UT, NH, CA, NJ, TN, NV, AZ, NE, IA, CT, ME, LA, KY, MS, MD, DC, GA, CO, KS, ID, MN, AR, HI, NM, WA, SD, OR, DE, WY, AK, and ND
Lot / Code Information
Driver UDI-DI: 00884662000574, UPN: 102-9800, All Lots. Superion Indirect Decompression System IFU (92479815-02), Superion IDS Kit IFU (92479820-02), Surgical Technique Manual (92479821-02)
Other Recalls from Boston Scientific Neuromodulation Cor...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2558-2025 | Class II | Vercise Deep Brain Stimulation Systems Surgical... | Jul 8, 2025 |
| Z-2340-2025 | Class II | Burr Hole Cover Kit, REF: M365DB4600C0; Burr H... | Jul 8, 2025 |
| Z-2485-2025 | Class II | Superion IDS Kit Superion Indirect Decompressi... | Jun 6, 2025 |
| Z-2617-2024 | Class II | WAVEWRITER ALPHA: Model: SC-1216, 16 IPG KIT, R... | Jul 17, 2024 |
| Z-1890-2024 | Class II | Vercise Genus Deep Brain Stimulation (DBS) Impl... | Apr 18, 2024 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.